ET-1 induces a strong and sustained pressor response in vessels 1 and systemic hypertension in the rat.
] -bradykinin, a bradykinin Bj receptor antagonist, captopril did not inhibit but rather stimulated endothelin-1 secretion, whereas bradykinin inhibited endothelin-1 secretion, and this inhibition by bradykinin was reversed by coincubation with A' ET-1 induces a strong and sustained pressor response in vessels 1 and systemic hypertension in the rat. 2 It also stimulates mitogenesis in vascular smooth muscle cells. 3 These studies suggest the potential importance of endothelin in the pathophysiology of hypertension 2 -4 and atherosclerosis. 3 Angiotensin I converting enzyme (ACE) inhibitors generally have been used as antihypertensive drugs. However, the precise mechanism of the antihypertensive effects of ACE inhibitors has not been fully elucidated. In addition, there is recent evidence for new important functions of ACE inhibitors in the cardiovascular field. ACE inhibitors can induce regression of intimal hyperplasia, whereas other antihypertensive drugs are ineffective in this regard. 5 Clinical trials in patients with chronic congestive heart failure demonstrated a significant reduction in mortality with ACE inhibitor therapy. 6 Although ACE inhibition diminishes the formation of a pressor peptide, angiotensin II, 7 it also diminishes degradation of kinins, which are vasodepressor peptides. 8 Bradykinin stimulates the synthesis of prostaglandin I 2 and endothelium-derived relaxing factor, 9 recently identified as nitric oxide (NO). 910 NO not only antagonizes the effects of ET-1 of vasoconstriction 11 and mitogenesis of From the Department of Geriatric Medicine, Osaka University Medical School (Japan).
Address for correspondence: Keisuke Fukuo, MD, Department of Geriatric Medicine, Osaka University Medical School, 2-2,Yamadaoka, Suita, Osaka 553, Japan. vascular smooth muscle cells 12 but also inhibits the production of ET-1 by endothelial cells. 13 Furthermore, ACE inhibitors stimulate the production of NO and prostaglandin I 2 mediated by B2 receptors in endothelial cells. 14 The present study therefore was performed to examine whether ACE inhibitor inhibits ET-1 secretion through the activation of B^ receptors in endothelial cells.
Methods

Materials
Captopril ]-bradykinin, des-Arg'-bradykinin, and Af°-nitro-L-arginine (L-NA) were purchased from the Peptide Institute, Osaka, Japan. Nitrate reductase was from Sigma Chemical Co., St. Louis, Mo. Other reagents were of the highest grade available.
Cells
Endothelial cells, isolated from human thoracic aortas, were purchased from Kurabo, Osaka, Japan, and cultured on collagen-coated dishes in modified MCDB 131 medium supplemented with 10% fetal calf serum at 37°C under 5% CO 2 in air. Cells at passages between 5 and 8 were used for the experiments and seeded at a density of 2x10* per well on collagen-coated 24-well plates. tion, the medium was collected in tubes and stored at -70°C until assay. The concentration of ET-1 was measured by a sensitive sandwich-enzyme immunoassay as described previously. 15 Protein concentrations were determined by the spectrophotometric method using Micro BCA Protein Assay Reagent (Pierce Chemical Co., Rockford, 111.) with bovine serum albumin as a standard.
FIGURE 1. Line graph shows dose-dependent effects of bradykinin (BK) on endothelin-1 (ET-1) secretion by endothelial cells. Cells were incubated with serum-free medium containing BK at concentrations indicated for 24 hours in presence (closed triangles) or absence (closed circles) of 3xlO'
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Nitrite and Nitrate Assay
Confluent cultures of cells in 24-well plates were preincubated with serum-free modified MCDB 131 medium with or without various agents for 24 hours. Nitrite plus nitrate concentration was determined after treatment of 0.1 mL supernatant with nitrate reductase. Nitrite concentration (NO 2 " plus NO 3 " reduced to NO 2 ") in the samples was determined with Greiss reagents. 16 
Statistical Analysis
Statistical analysis was performed by one-way analysis of variance. Results are expressed as mean±SEM. A value of p<0.05 was considered significant.
Results
After 24 hours of incubation of endothelial cells with serum-free medium, ET-1 concentration in the control culture was 1,321 ±42 pg/mg cell protein (n=6). Treatment of endothelial cells with bradykinin at concentrations from 10" 7 to 10" 5 M significantly inhibited this basal secretion of ET-1 (Figure 1 ). This inhibition by bradykinin was partially reversed by coincubation with 3xlO~3 M L-NA, an inhibitor of NO synthesis, at a higher concentration than that of L-arginine in the medium (3x10"" M).
Incubation of endothelial cells with captopril at concentrations of 10" We next examined whether captopril enhances NO production in cultured endothelial cells. As shown in Figure 4 , 10" 7 M captopril significantly enhanced NO production by endothelial cells. The B, receptor antagonist at 10" 6 M did not affect this enhancement of NO production by captopril. In contrast, the B 2 receptor antagonist at 10~6 M attenuated this enhancement of NO production by captopril. Although 10" 7 M bradykinin significantly enhanced NO production, the B] receptor agonist at 10~7 M did not affect NO production. Furthermore, bradykinin-induced NO production was completely inhibited by 10~6 M Bj receptor antagonist but not by 1CT 6 M B! receptor antagonist.
Discussion
The present study demonstrates that the ACE inhibitor captopril inhibits the basal secretion of ET-1 by vascular endothelial cells. Coincubation with L-NA, an inhibitor of NO synthesis, reversed the inhibition by captopril. Furthermore, captopril actually enhanced NO synthesis in endothelial cells, suggesting that NO participates in this inhibition of ET-1 secretion by captopril.
Recently, Yoshida and Nakamura 17 also reported that ACE inhibitors inhibit 5% calf serum-stimulated ET-1 secretion but not the basal secretion of ET-1 by endothelial cells. However, they did not consider the participation of bradykinin or NO in the cellular mechanism of this inhibitory effect of ACE inhibitors. ACE inhibition decreases not only formation of angiotensin II 8 but also degradation of kinins. 18 In cultured human and bovine endothelial cells, ACE inhibitors elevate intraceUnlar calcium concentrations and stimulate the production of NO and prostaglandin I 2 via Bj receptors. 14 In the present study, the enhancement of NO production by captopril was inhibited by coincubation with the Bj receptor antagonist. In addition, our preliminary experiments revealed that the concentration of bradykinin in the medium, determined by a specific radioimmunoassay kit (Otsuka Pharmaceutical Co. Ltd.), increased from 0.08±0.01 to 3.17±0.14 ng/mL (mean±SEM, n=6) after 24 hours of incubation of endothelial cells with 10~7 M captopril. Although the medium concentration of bradykinin in 10"
7 M captopril-treated cells was lower than that of exogenous bradykinin, which inhibited ET-1 secretion to the same degree as incubation with 10~7 M captopril, it has been reported that inhibition of bradykinin degradation by captopril potentiates the vasodilator effect of bradykinin in rat mesenteric arteries. 19 Furthermore, ACE inhibition by ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endotheliumderived bradykinin. 20 Therefore, accumulation of endogenous bradykinin by the inhibition of bradykinin degradation could be responsible for the inhibition of ET-1 secretion by captopril from endothelial cells.
Bradykinin, produced from kininogen by the action of kallikrein, has a variety of physiological and pharmacological effects on the vascular system; physiologically it induces endothelium-dependent relaxation of arteries. 21 However, it also induces contraction of arteries 22 and veins. 23 These different effects of bradykinin on arteries have been explained by the existence of bradykinin receptor subtypes. 22 Endothelial cells possess low-affinity B, receptors and high-affinity B 2 receptors. 24 In this study, bradykinin-induced stimulation of NO production was inhibited by the B2 receptor antagonist but not by the B, receptor antagonist. Because bradykinininduced suppression of ET-1 secretion was reversed by L-NA, enhancement of NO production via the Br eceptor may participate in the suppression of ET-1 secretion by bradykinin. In contrast, coincubation with B, receptor antagonist did not reverse but rather enhanced the bradykinin-induced suppression of ET-1 secretion. Furthermore, the B, receptor agonist did not affect NO production but significantly stimulated ET-1 secretion by the endothelial cells. Thus, although bradykinin physiologically inhibits ET-1 secretion by enhancing NO production via B? receptors, bradykinin can stimulate ET-1 secretion when B, receptor pathways are more activated than B2 receptor pathways in endothelial cells. In addition, the enhancement of NO production by captopril was inhibited by B 2 receptor antagonist but not by B^ receptor antagonist. Furthermore, although captopril alone inhibited the secretion of ET-1, it stimulated ET-1 secretion when captopril-induced enhancement of NO production was inhibited by coincubation with B2 receptor antagonist. These results suggest that captopril suppresses ET-1 secretion by the accumulation of endogenous bradykinin in endothelial cells under physiological conditions. However, captopril can stimulate ET-1 secretion under pathological conditions in which endothelial cells possess predominantly B[ receptors rather than B 2 receptors.
